[1] Guariguata L, Whiting DR, Hambleton I, et al.Global estimates of diabetes prevalence for 2013 and projections for 2035[J]. Diabetes Res Clin Pract, 2014, 103(2):137-149. [2] Kuecker CM, Vivian EM.Patient considerations in type 2 diabetes-role of combination dapagliflozin-metformin XR[J]. Diabetes Metab Syndr Obes, 2016, 9(3):25-35. [3] Hossain P, Kawar B, EI Nahas M.Obesity and diabetes in the developing world-a growing challenge[J]. N Engl J Med, 2007, 356(3):213-215. [4] Islam MS, Loots du T. Experimental rodent models of type 2 diabetes: a review[J]. Methods Find Exp Clin Pharmacol, 2009, 31(4):249-261. [5] Srinivasan K, Ramarao P.Animal models in type 2 diabetes research: an overview[J]. Indian J Med Res, 2007, 125(3):451-472. [6] Stumvoll M, Goldstein BJ, van Haeften TW. Type 2 diabetes: pathogenesis and treatment[J]. Lancet, 2008, 371(9631):2153-2156. [7] Zimmet P, Alberti KG, Shaw J.Global and societal implications of the diabetes epidemic[J]. Nature, 2001, 414(6865):782-787. [8] Islam MS.Animal models of diabetic neuropathy: progress since 1960s[J]. J Diabetes Res, 2013, 9(2013):1-9. [9] Ludwig J, Sanbonmatsu L, Gennetian L, et al.Neighborhoods, obesity, and diabetes-a randomized social experiment[J]. N Engl J Med, 2011, 365(16):1509-1519. [10] 刘俊, 郭毅, 刘晴, 等. 超重、肥胖与型糖尿病相关性的分析[J]. 中国循证医学杂志, 2013, 13(2):190-195. |